Literature DB >> 11572863

The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease.

Y Chai1, L Wu, J D Griffin, H L Paulson.   

Abstract

Intracellular inclusions are a unifying feature of polyglutamine (polyQ) neurodegenerative diseases, yet each polyQ disease displays a unique pattern of neuronal degeneration. This implies that the protein context of expanded polyQ plays an important role in establishing selective neurotoxicity. Here, in studies of the spinocerebellar ataxia type 3 disease protein ataxin-3, we demonstrate that the protein sequence surrounding polyQ specifies the constituents of nuclear inclusions (NI) formed by the disease protein. The nuclear proteins cAMP response element-binding protein-binding protein (CBP) and Mastermind-like-1 strongly colocalize only to NI formed by full-length ataxin-3, whereas the splicing factor SC35 colocalizes only to NI formed by a polyQ-containing, carboxyl-terminal fragment of ataxin-3. These differences in NI formation reflect specific protein interactions normally undertaken by ataxin-3, as both normal and mutant full-length ataxin-3 co-immunoprecipitate with CBP and sediment on density gradients as macromolecular complexes. Moreover, normal ataxin-3 represses cAMP response element-binding protein-mediated transcription, indicating a functional consequence of ataxin-3 interactions with CBP. Finally, we show that mutant ataxin-3 forms insoluble intranuclear complexes, or microaggregates, before NI can be detected, implying a precursor-product relationship. These results suggest that protein context-dependent recruitment of nuclear proteins to intranuclear microaggregates, and subsequently to NI, may contribute to selective neurotoxicity in polyQ diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572863     DOI: 10.1074/jbc.M106575200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

3.  Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.

Authors:  Lianwu Fu; Ya-sheng Gao; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2005-06-16       Impact factor: 5.996

4.  Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.

Authors:  Peter Breuer; Annette Haacke; Bernd O Evert; Ullrich Wüllner
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

Review 5.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 6.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

7.  Ubiquilin-2 differentially regulates polyglutamine disease proteins.

Authors:  Julia E Gerson; Nathaniel Safren; Svetlana Fischer; Ronak Patel; Emily V Crowley; Jacqueline P Welday; Alexandra K Windle; Sami Barmada; Henry L Paulson; Lisa M Sharkey
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

8.  Efficient induction of nuclear aggresomes by specific single missense mutations in the DNA-binding domain of a viral AP-1 homolog.

Authors:  Richard Park; Ruth Wang'ondu; Lee Heston; Duane Shedd; George Miller
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

9.  Interaction of selected divalent metal ions with human ataxin-3 Q36.

Authors:  Iwona Stawoska; Aleksandra Wesełucha-Birczyńska; Maria Elena Regonesi; Matteo Riva; Paolo Tortora; Grazyna Stochel
Journal:  J Biol Inorg Chem       Date:  2009-07-04       Impact factor: 3.358

10.  The structural impact of a polyglutamine tract is location-dependent.

Authors:  Amy L Robertson; James Horne; Andrew M Ellisdon; Bronwen Thomas; Martin J Scanlon; Stephen P Bottomley
Journal:  Biophys J       Date:  2008-10-10       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.